

Susceptibility, Mycobacterium tuberculosis
Complex, Second Line, Varies

Patient ID SA00150731	Patient Name VALIDATIONTESTING, TB2LN POS	Birth Date 1988-01-01	Gender F	Age 34
Order Number SA00150731	Client Order Number SA00150731	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 15 Feb 2022 00:00		

Susceptibility, Mtb Complex, 2 Line

1 MCR



SOURCE: PELVIS, pelvis - mtb complex

Abn

SUSCEPTIBILITY, MTB COMPLEX, 2 LINE
FINAL
MYCOBACTERIUM TUBERCULOSIS COMPLEX

Organism identified by client.

Second line agents tested by microbroth dilution with the MIC reported using laboratory developed interpretive criteria.

Organism: MYCOBACTERIUM TUBERCULOSIS COMPLEX

Antibiotic	MIC (mcg/mL)	Interpretation
Amikacin	16	R
Ethionamide	10	R
Kanamycin	10	R
Moxifloxacin	8	R
Ofloxacin	4	R
p-Aminosalicylic acid	4	R
Rifabutin	0.25	R
Streptomycin	4	R

S=SUSCEPTIBLE I=INTERMEDIATE R=RESISTANT
NS=NONSUSCEPTIBLE SDD=SUSCEPTIBLE DOSE
DEPENDENT

Received: 16 Feb 2022 12:43

Reported: 16 Feb 2022 12:57

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292